FMP

FMP

Enter

ACIU - AC Immune SA

Financial Summary of AC Immune SA(ACIU), AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines

photo-url-https://financialmodelingprep.com/image-stock/ACIU.png

AC Immune SA

ACIU

NASDAQ

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

3.48 USD

-0.15 (-4.31%)

About

ceo

Dr. Andrea Pfeifer Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is ...

CIK

0001651625

ISIN

CH0329023102

CUSIP

H00263105

Address

Building B

Phone

41 21 345 91 21

Country

CH

Employee

133

IPO Date

Sep 23, 2016

Summary

CIK

0001651625

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

H00263105

ISIN

CH0329023102

Country

CH

Price

3.48

Beta

1.27

Volume Avg.

875.18k

Market Cap

345.21M

Shares

-

52-Week

2.2-5.14

DCF

0.65

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-5.12

P/B

-

Website

https://www.acimmune.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ACIU News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep